Furthermore, a number of less common serological and molecular markers have also shown prognostic evidence, such as the estrogen receptor, progesterone receptor, human epidermal growth factor receptor-2 in breast cancer and mismatch repair gene in stage II CRC (6,7). This evidence concerns the gene ERBB2 and breast carcinoma.